Skip to main content
SpringerLink
Log in

RA biologicals (± DMARDs) increase serious infections

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The approved biological drugs included tumour necrosis factor inhibitors (e.g. etanercept, adalimumab, infliximab, golimumab, certolizumab pegol), interleukin (IL)-1 antagonist (anakinra), IL-6 antagonist (tocilizumab), anti-CD28 (abatacept), and anti-B cell (rituximab) biologicals in any dose.

References

  1. Singh JA, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet : [8 pages], 12 May 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)61704-9

  2. Dixon WG. Rheumatoid arthritis: biological drugs and risk of infection. Lancet : [2 pages], 12 May 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)61907-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

RA biologicals (± DMARDs) increase serious infections. Reactions Weekly 1552, 12 (2015). https://doi.org/10.1007/s40278-015-0808-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-0808-2

Search

Navigation